Fondazione Ricerca Traslazionale

This study is testing whether adding a second drug (bevacizumab) to a standard immunotherapy (atezolizumab) works better for people with a specific type of advanced lung cancer. It involves 206 patients in Italy who have not had chemotherapy before and whose tumors test positive …

This study is testing whether adding an experimental cancer vaccine called Tedopi to standard second-line drugs (docetaxel or nivolumab) can help control metastatic lung cancer that has progressed after initial treatment. It will involve about 105 patients who have a specific gen…